InvestorsHub Logo
Followers 57
Posts 5697
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Tuesday, 01/24/2017 11:57:02 AM

Tuesday, January 24, 2017 11:57:02 AM

Post# of 6034
2017 Targeted Goals

+ Complete enrollment for HS-110/ nivolumab combo Ph 1b trial
+ Report additional topline data for HS-110/nivolumab combo data
+ Open additional trial arms to evaluate HS-110 with new I-O combinations
+ Report topline 2-year data for HS-410 Ph 2 trial
+ In-license new programs to complement existing T cell-activating technologies
+ Pursue non-dilutive grant funding to advance existing programs

Focused on I-O combinations that have the potential to dramatically improve patient outcomes

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News